About
Arun Swaminathan is a biotech executive at Coya Therapeutics, where he became Chief Executive Officer on November 1, 2024 after previously serving as Chief Business Development Officer. Coya is a clinical-stage biotechnology company focused on Treg-based therapies for neurodegenerative, autoimmune, and metabolic diseases. The available primary sources support his Coya affiliation; the 'BioAge' label appears likely to be a database mis-association rather than a verified current role.
Areas of interest
biotechpharmaceuticalsbusiness developmentlicensingstrategic partnershipsneuroinflammationALSimmunologyautoimmune diseasemetabolic diseaseoncologytargeted radiotherapies